Rajeev M. Shah - 16 Jun 2021 Form 4 Insider Report for Solid Biosciences Inc. (SLDB)

Reporting relationship: Director, 10%+ Owner
Issuer ticker: SLDB
Reported as of: 16 Jun 2021
Net transaction value: $0
SEC form: 4
Accepted by SEC: 21 Jun 2021, 16:00:16 UTC
Prior SEC filing: 21 May 2021
Next SEC filing: 21 Jun 2021
Source filing: View source filing
Reporting owner signature: /s/ by Erin P. Brennan as attorney-in-fact for Rajeev M. Shah

Key filing fact

Rajeev M. Shah filed Form 4 for Solid Biosciences Inc. (SLDB) on 21 Jun 2021.

Key facts

This page summarizes Rajeev M. Shah's Form 4 filing for Solid Biosciences Inc. (SLDB).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 21 Jun 2021, 16:00.

Change

Previous filing in this sequence was filed on 21 May 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SLDB transaction Derivative

Director Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +30,000
Change %
Price: $0.000000
Shares after: 30,000
Date: 16 Jun 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 30,000
Exercise price: $3.94
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

This option was granted on June 16, 2021 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events.

Footnote F2

Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.

SEC remarks

Exhibit Index: 24.1 Power of Attorney